Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Magee Equation (Est. Oncotype DX®)

The Magee Equations are prediction models that estimate the Oncotype DX® Recurrence Score (RS) using standard pathology variables (Nottingham Score, Ki-67, ER/PR H-Scores, Tumor Size).

Evidence-based context for fast calculator use

Purpose:
Magee Equation estimates Oncotype DX Recurrence Score from standard breast cancer pathology to guide decisions on genomic testing need.
Population:
patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment
Factors:
Nottingham Prognostic Score, ER H-Score, PR H-Score, Ki-67 Index, Tumor Size
Reference:
Klein ME, Dabbs DJ, Shuai Y, et al. Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by a linear regression model. Mod Pathol. 2013;26(5):658-664.
HomeMagee Equation (Est. Oncotype DX®)
Pin your most used calculators here by clicking the star in the dropdown.

Magee Equation (Est. Oncotype DX®)

points
H-score
H-score
%
cm

Clinical Context & Background

The Magee Equations are prediction models that estimate the Oncotype DX® Recurrence Score (RS) using standard pathology variables (Nottingham Score, Ki-67, ER/PR H-Scores, Tumor Size). This helps clinicians identify patients who are likely to have a low RS and might avoid expensive genomic testing.
Primary Source EvidenceKlein ME, Dabbs DJ, Shuai Y, et al. Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by a linear regression model. Mod Pathol. 2013;26(5):658-664.
Formula Logic
RS ≈ 15.31 + (1.50 × Nottingham) - (0.05 × ER H-Score) - (0.03 × PR H-Score) + (0.14 × Ki67) + (0.54 × Tumor Size)

Reference Data

Est. Recurrence ScoreRisk Category (TAILORx)
0 - 25Low / Intermediate Risk
26 - 100High Risk

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use Magee Equation (Est. Oncotype DX®) when magee Equation estimates Oncotype DX Recurrence Score from standard breast cancer pathology to guide decisions on genomic testing need.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning 0 - 25 through 26 - 100.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Integrate the result with invasive versus in-situ status, stage, receptor biology, treatment timing, genomic testing, comorbidity, and patient goals.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Do not interchange screening-risk, DCIS, invasive prognosis, genomic, and post-neoadjuvant tools.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment

How to apply this result

For a representative case, verify Nottingham Prognostic Score, ER H-Score, PR H-Score, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Breast Cancer hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

BI-RADS Score (Breast)Nottingham Prognostic Index (NPI)MSKCC DCIS Nomogram — Breast Cancer DCIS Recurrence Risk Calculator

Frequently Asked Questions

When should Magee Equation (Est. Oncotype DX®) be used?

Use it for patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment when all required inputs and the intended clinical setting are confirmed.

Can Magee Equation (Est. Oncotype DX®) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.